Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes

Hiroko Kita-Matsuo, Maria Barcova, Natalie Prigozhina, Nathan Salomonis, Karen Wei, Jeffrey G. Jacot, Brandon Nelson, Sean Spiering, René Haverslag, Changsung Kim, Maria Talantova, Ruchi Bajpai, Diego Calzolari, Alexey Tershikh, Andrew D. McCulloch, Jeffrey H. Price, Bruce R. Conklin, H. S Vincent Chen, Mark Mercola

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Background: Developmental, physiological and tissue engineering studies critical to the development of successful myocardial regeneration therapies require new ways to effectively visualize and isolate large numbers of fluorescently labeled, functional cardiomyocytes. Methodology/Principal Findings: Here we describe methods for the clonal expansion of engineered hESCs and make available a suite of lentiviral vectors for that combine Blasticidin, Neomycin and Puromycin resistance based drug selection of pure populations of stem cells and cardiomyocytes with ubiquitous or lineage-specific promoters that direct expression of fluorescent proteins to visualize and track cardiomyocytes and their progenitors. The phospho-glycerate kinase (PGK) promoter was used to ubiquitously direct expression of histone-2B fused eGFP and mCherry proteins to the nucleus to monitor DNA content and enable tracking of cell migration and lineage. Vectors with T/Brachyury and α-myosin heavy chain (αMHC) promoters targeted fluorescent or drug-resistance proteins to early mesoderm and cardiomyocytes. The drug selection protocol yielded 96% pure cardiomyocytes that could be cultured for over 4 months. Puromycin-selected cardiomyocytes exhibited a gene expression profile similar to that of adult human cardiomyocytes and generated force and action potentials consistent with normal fetal cardiomyocytes, documenting these parameters in hESC-derived cardiomyocytes and validating that the selected cells retained normal differentiation and function. Conclusion/Significance: The protocols, vectors and gene expression data comprise tools to enhance cardiomyocyte production for large-scale applications.

Original languageEnglish (US)
Article numbere5046
JournalPLoS One
Volume4
Issue number4
DOIs
StatePublished - Apr 8 2009
Externally publishedYes

Fingerprint

drug resistance
Drug Resistance
Cardiac Myocytes
Puromycin
glycerate kinase
Gene expression
Pharmaceutical Preparations
Proteins
Neomycin
Myosin Heavy Chains
Stem cells
Tissue engineering
Histones
puromycin
promoter regions
DNA
Human Embryonic Stem Cells
cardiomyocytes
drugs
tissue engineering

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. / Kita-Matsuo, Hiroko; Barcova, Maria; Prigozhina, Natalie; Salomonis, Nathan; Wei, Karen; Jacot, Jeffrey G.; Nelson, Brandon; Spiering, Sean; Haverslag, René; Kim, Changsung; Talantova, Maria; Bajpai, Ruchi; Calzolari, Diego; Tershikh, Alexey; McCulloch, Andrew D.; Price, Jeffrey H.; Conklin, Bruce R.; Chen, H. S Vincent; Mercola, Mark.

In: PLoS One, Vol. 4, No. 4, e5046, 08.04.2009.

Research output: Contribution to journalArticle

Kita-Matsuo, H, Barcova, M, Prigozhina, N, Salomonis, N, Wei, K, Jacot, JG, Nelson, B, Spiering, S, Haverslag, R, Kim, C, Talantova, M, Bajpai, R, Calzolari, D, Tershikh, A, McCulloch, AD, Price, JH, Conklin, BR, Chen, HSV & Mercola, M 2009, 'Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes', PLoS One, vol. 4, no. 4, e5046. https://doi.org/10.1371/journal.pone.0005046
Kita-Matsuo, Hiroko ; Barcova, Maria ; Prigozhina, Natalie ; Salomonis, Nathan ; Wei, Karen ; Jacot, Jeffrey G. ; Nelson, Brandon ; Spiering, Sean ; Haverslag, René ; Kim, Changsung ; Talantova, Maria ; Bajpai, Ruchi ; Calzolari, Diego ; Tershikh, Alexey ; McCulloch, Andrew D. ; Price, Jeffrey H. ; Conklin, Bruce R. ; Chen, H. S Vincent ; Mercola, Mark. / Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. In: PLoS One. 2009 ; Vol. 4, No. 4.
@article{c8d0b0457ff94c438acc5aa5e12ade52,
title = "Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes",
abstract = "Background: Developmental, physiological and tissue engineering studies critical to the development of successful myocardial regeneration therapies require new ways to effectively visualize and isolate large numbers of fluorescently labeled, functional cardiomyocytes. Methodology/Principal Findings: Here we describe methods for the clonal expansion of engineered hESCs and make available a suite of lentiviral vectors for that combine Blasticidin, Neomycin and Puromycin resistance based drug selection of pure populations of stem cells and cardiomyocytes with ubiquitous or lineage-specific promoters that direct expression of fluorescent proteins to visualize and track cardiomyocytes and their progenitors. The phospho-glycerate kinase (PGK) promoter was used to ubiquitously direct expression of histone-2B fused eGFP and mCherry proteins to the nucleus to monitor DNA content and enable tracking of cell migration and lineage. Vectors with T/Brachyury and α-myosin heavy chain (αMHC) promoters targeted fluorescent or drug-resistance proteins to early mesoderm and cardiomyocytes. The drug selection protocol yielded 96{\%} pure cardiomyocytes that could be cultured for over 4 months. Puromycin-selected cardiomyocytes exhibited a gene expression profile similar to that of adult human cardiomyocytes and generated force and action potentials consistent with normal fetal cardiomyocytes, documenting these parameters in hESC-derived cardiomyocytes and validating that the selected cells retained normal differentiation and function. Conclusion/Significance: The protocols, vectors and gene expression data comprise tools to enhance cardiomyocyte production for large-scale applications.",
author = "Hiroko Kita-Matsuo and Maria Barcova and Natalie Prigozhina and Nathan Salomonis and Karen Wei and Jacot, {Jeffrey G.} and Brandon Nelson and Sean Spiering and Ren{\'e} Haverslag and Changsung Kim and Maria Talantova and Ruchi Bajpai and Diego Calzolari and Alexey Tershikh and McCulloch, {Andrew D.} and Price, {Jeffrey H.} and Conklin, {Bruce R.} and Chen, {H. S Vincent} and Mark Mercola",
year = "2009",
month = "4",
day = "8",
doi = "10.1371/journal.pone.0005046",
language = "English (US)",
volume = "4",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes

AU - Kita-Matsuo, Hiroko

AU - Barcova, Maria

AU - Prigozhina, Natalie

AU - Salomonis, Nathan

AU - Wei, Karen

AU - Jacot, Jeffrey G.

AU - Nelson, Brandon

AU - Spiering, Sean

AU - Haverslag, René

AU - Kim, Changsung

AU - Talantova, Maria

AU - Bajpai, Ruchi

AU - Calzolari, Diego

AU - Tershikh, Alexey

AU - McCulloch, Andrew D.

AU - Price, Jeffrey H.

AU - Conklin, Bruce R.

AU - Chen, H. S Vincent

AU - Mercola, Mark

PY - 2009/4/8

Y1 - 2009/4/8

N2 - Background: Developmental, physiological and tissue engineering studies critical to the development of successful myocardial regeneration therapies require new ways to effectively visualize and isolate large numbers of fluorescently labeled, functional cardiomyocytes. Methodology/Principal Findings: Here we describe methods for the clonal expansion of engineered hESCs and make available a suite of lentiviral vectors for that combine Blasticidin, Neomycin and Puromycin resistance based drug selection of pure populations of stem cells and cardiomyocytes with ubiquitous or lineage-specific promoters that direct expression of fluorescent proteins to visualize and track cardiomyocytes and their progenitors. The phospho-glycerate kinase (PGK) promoter was used to ubiquitously direct expression of histone-2B fused eGFP and mCherry proteins to the nucleus to monitor DNA content and enable tracking of cell migration and lineage. Vectors with T/Brachyury and α-myosin heavy chain (αMHC) promoters targeted fluorescent or drug-resistance proteins to early mesoderm and cardiomyocytes. The drug selection protocol yielded 96% pure cardiomyocytes that could be cultured for over 4 months. Puromycin-selected cardiomyocytes exhibited a gene expression profile similar to that of adult human cardiomyocytes and generated force and action potentials consistent with normal fetal cardiomyocytes, documenting these parameters in hESC-derived cardiomyocytes and validating that the selected cells retained normal differentiation and function. Conclusion/Significance: The protocols, vectors and gene expression data comprise tools to enhance cardiomyocyte production for large-scale applications.

AB - Background: Developmental, physiological and tissue engineering studies critical to the development of successful myocardial regeneration therapies require new ways to effectively visualize and isolate large numbers of fluorescently labeled, functional cardiomyocytes. Methodology/Principal Findings: Here we describe methods for the clonal expansion of engineered hESCs and make available a suite of lentiviral vectors for that combine Blasticidin, Neomycin and Puromycin resistance based drug selection of pure populations of stem cells and cardiomyocytes with ubiquitous or lineage-specific promoters that direct expression of fluorescent proteins to visualize and track cardiomyocytes and their progenitors. The phospho-glycerate kinase (PGK) promoter was used to ubiquitously direct expression of histone-2B fused eGFP and mCherry proteins to the nucleus to monitor DNA content and enable tracking of cell migration and lineage. Vectors with T/Brachyury and α-myosin heavy chain (αMHC) promoters targeted fluorescent or drug-resistance proteins to early mesoderm and cardiomyocytes. The drug selection protocol yielded 96% pure cardiomyocytes that could be cultured for over 4 months. Puromycin-selected cardiomyocytes exhibited a gene expression profile similar to that of adult human cardiomyocytes and generated force and action potentials consistent with normal fetal cardiomyocytes, documenting these parameters in hESC-derived cardiomyocytes and validating that the selected cells retained normal differentiation and function. Conclusion/Significance: The protocols, vectors and gene expression data comprise tools to enhance cardiomyocyte production for large-scale applications.

UR - http://www.scopus.com/inward/record.url?scp=65249179464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249179464&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0005046

DO - 10.1371/journal.pone.0005046

M3 - Article

VL - 4

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e5046

ER -